Single Center Evaluation of Patients with Therapy and Prior-Malignancy Related Acute Lymphoblastic Leukemia and the Use of Hematopoietic Stem Cell Transplants
Transplantation and Cellular Therapy(2024)
Abstract
Background
Therapy-related (t-ALL) and previous malignancy-related acute lymphoblastic leukemia (pm-ALL) are a subset of ALL that arise after treatment of prior malignancy. Recent reports indicate that allogeneic hematopoietic stem cell transplantation (HCT) may yield comparable outcomes in t-ALL when compared to pm-ALL, however data remains limited in both diagnostic criteria and highest risk factors for worse prognosis. This single-center analysis aims to shed light on the unique behavior of t-ALL and pm-ALL with and without HCT.
Methods and Patient Selection
We collected all cases of ALL treated at our institution from 2000 to 2023; acute lymphoblastic lymphoma was excluded. Cases of t-ALL were defined as any ALL diagnosed after exposure to chemotherapy or XRT prior to leukemia diagnosis, whereby pm-ALL had documented prior malignancy, but having only undergone surgery or observation.
Results
We identified 264 patients diagnosed with ALL who noted previous malignancy, 198 (74%) patients considered to have t-ALL, and 68 (26%) were identified as pm-ALL, demographics of both are included in Table 1. The most common previous malignancies were breast (18%), non-melanoma skin (12%), prostate (10%), and myeloma (9%). HCT was performed in 38 (14%) patients. Therapy for primary malignancy can be seen in Table 1. Average age of patient at diagnosis was 57 years (range, 45-62 years) and 66 years (range 55-73 years) for those who underwent HCT and those who did not, respectively. Rates of proceeding to transplant were roughly similar in t-ALL vs pm-ALL. Five-year overall survival (OS) was comparable between t-ALL and pm-ALL (Figure 1). The 5-year OS in those receiving HCT was 52.5% (range, 34.9-70.1%) and 33.1% [25.6-40.7%] in those who did not (Figure 2A and B). Within t-ALL, those who received prior chemotherapy with or without XRT had a 5-year OS of 45.2% [31.7-58.6%] and 27.5% [13.6-41.4%] respectively (Figure 3). Outcomes when comparing previous malignancy type (solid vs. liquid) were similar.
Conclusion
In our single-center analysis, t-ALL and pm-ALL fared comparably, and there did not appear to be any distinct predictors of outcomes. Larger, multi-center analyses are needed to better elucidate predictors of prognosis, and to inform selection of patients who may benefit from intensive consolidation such as allogeneic HCT.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined